According to FutureWise analysis the market for Caspofungin in 2023 is US$ 0.51 billion, and is expected to reach US$ 0.61 billion by 2031 at a CAGR of 2.20%.
Caspofungin is a lipopeptide antifungal drug which does not take the enzyme known as β-D-glucan synthesis, which disrupts the wall of the fungal cell. The product is an important factor of new antifungal class and is regarded as Echinocandins. The usage of product β-D-glucan synthesizer has been FDA approved and sanctioned. It is inserted into the body intravenously by injection.
An augmentation in the volume of invasive candidiasis, growth in the usage of echinocandins, a better purchasing power and disposable income of the consumers in developing nations and the spread of awareness amongst the population regarding the preventive components of myriad microbial illness are all factors which are likely to drive the market growth.
Candida species is ranked among the top ten of pathogenic infection contracted in hospitals and is listed as the fourth for pathogenic infections in nosocomial bloodstream. All these factors represent potential market growth in the forecast period. Moreover, it is to be noted that the rise in the patient pool of chronic diseases such as cancer and diabetes and a spur in the geriatric population, which are vulnerable candidates to such ailments, are patterns which are likely to project significant market value. In addition, a large number of people are aware of the technological innovations of new areas of treatment and social acceptance of such treatment will, most likely, render an expansion of the caspofungin market size.
The market for caspofungin has been fragmented on the basis of indication, the distribution channel and even region. Going by the indication, the market has been bifurcated into thrush and candidiasis. With this segment, candidiasis is estimated to hold some of the largest market share in the worldwide market during the forecast time span. Caspofungin has been regulated and sanctioned as the first phase of treatment for those patients afflicted with invasive candidiasis and are skeptical towards other kinds of antifungal agents. It is shown to be adopted as the first phase of treatment for diverse forms of candidiasis, namely, intra-abdominal abscesses, pleural space infections, esophageal candidiasis and peritonitis. Most people ideally opt for caspofungin in place of other antifungals in various diseases. All these market trends are projected to revitalize the economic growth of the market. In the case of distribution channel, the market has been categorized into hospital, retail and online pharmacies.